scispace - formally typeset
Open AccessJournal ArticleDOI

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.

Mikhail Kosiborod, +36 more
- 01 Sep 2021 - 
- Vol. 9, Iss: 9, pp 586-594
Reads0
Chats0
TLDR
The DARE-19 trial as discussed by the authors was a randomized, double-blind, placebo-controlled trial of patients hospitalised with COVID-19 and with at least one cardiometabolic risk factor (i.e., hypertension, type 2 diabetes, atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease).
About: 
This article is published in The Lancet Diabetes & Endocrinology.The article was published on 2021-09-01 and is currently open access. It has received 118 citations till now. The article focuses on the topics: Dapagliflozin & Organ dysfunction.

read more

Citations
More filters
Journal ArticleDOI

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Melanie J. Davies, +13 more
- 23 Sep 2022 - 
TL;DR: A panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019, concludes that there is a greater emphasis on weight management as part of the holistic approach to diabetes management.
Journal ArticleDOI

Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Melanie J. Davies, +13 more
- 24 Sep 2022 - 
TL;DR: The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycaemia in type 2 diabetes in adults, published since 2006 and last updated in 2019 as discussed by the authors .
Journal ArticleDOI

COVID-19 and metabolic disease: mechanisms and clinical management.

Charlotte Steenblock, +35 more
- 04 Oct 2021 - 
TL;DR: In this paper, the authors provide an update on the mechanisms of how metabolic and endocrine disorders might predispose patients to develop severe COVID-19 and post-pandemic.
Journal ArticleDOI

KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.

Peter Rossing, +16 more
- 01 Nov 2022 - 
TL;DR: In this paper , a supplement supported by the International Society of Nephrology and Kidney Disease: Improving Global Outcomes (KDIGO) is published as part of a professional education supplement.
Journal ArticleDOI

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

- 01 Nov 2022 - 
TL;DR: A systematic review and meta-analysis of SGLT2 inhibitor trials was conducted in this article , where the main outcomes were kidney disease progression (standardised to a definition of a sustained ≥50% decrease in estimated glomerular filtration rate [eGFR] from randomisation, a sustained low eGFR, end-stage kidney disease, or death from kidney failure), acute kidney injury, and a composite of cardiovascular death or hospitalisation for heart failure.
References
More filters
Journal ArticleDOI

Clinical Characteristics of Coronavirus Disease 2019 in China.

Wei-jie Guan, +36 more
- 28 Feb 2020 - 
TL;DR: During the first 2 months of the current outbreak, Covid-19 spread rapidly throughout China and caused varying degrees of illness, and patients often presented without fever, and many did not have abnormal radiologic findings.
Journal ArticleDOI

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Bernard Zinman, +11 more
- 25 Nov 2015 - 
TL;DR: Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care.
Journal ArticleDOI

Remdesivir for the Treatment of Covid-19 - Final Report.

John H. Beigel, +39 more
- 22 May 2020 - 
TL;DR: The data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection.
Journal ArticleDOI

Canagliflozin and cardiovascular and renal events in type 2 diabetes

Bruce Neal, +10 more
- 12 Jun 2017 - 
TL;DR: Patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal.
Journal ArticleDOI

Dexamethasone in Hospitalized Patients with Covid-19

Peter Horby, +25 more
- 17 Jul 2020 - 
TL;DR: In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support.
Related Papers (5)

Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes.

Jin-Kui Yang, +3 more
- 01 Sep 2010 - 

Practical recommendations for the management of diabetes in patients with COVID-19.

Stefan R. Bornstein, +23 more
- 23 Apr 2020 - 

Dexamethasone in Hospitalized Patients with Covid-19

Peter Horby, +25 more
- 17 Jul 2020 - 

Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study.

Sebastiano Bruno Solerte, +30 more
- 23 Sep 2020 - 

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, +798 more
- 27 Oct 2018 -